Literature DB >> 27421304

Analysis of Cancer-Targeting Alkylphosphocholine Analogue Permeability Characteristics Using a Human Induced Pluripotent Stem Cell Blood-Brain Barrier Model.

Paul A Clark, Abraham J Al-Ahmad1, Tongcheng Qian, Ray R Zhang, Hannah K Wilson, Jamey P Weichert2, Sean P Palecek, John S Kuo, Eric V Shusta.   

Abstract

Cancer-targeting alkylphosphocholine (APC) analogues are being clinically developed for diagnostic imaging, intraoperative visualization, and therapeutic applications. These APC analogues derived from chemically synthesized phospholipid ethers were identified and optimized for cancer-targeting specificity using extensive structure-activity studies. While they strongly label human brain cancers associated with disrupted blood-brain barriers (BBB), APC permeability across intact BBB remains unknown. Three of our APC analogues, CLR1404 (PET radiotracer), CLR1501 (green fluorescence), and CLR1502 (near-infrared fluorescence), were tested for permeability across a BBB model composed of human induced pluripotent stem cell-derived brain microvascular endothelial cells (iPSC-derived BMECs). This in vitro BBB system has reproducibly consistent high barrier integrity marked by high transendothelial electrical resistance (TEER > 1500 Ω-cm(2)) and functional expression of drug efflux transporters. The radioiodinated and fluorescent APC analogues demonstrated fairly low permeability across the iPSC-BMEC (35 ± 5.7 (CLR1404), 54 ± 3.2 (CLR1501), and 26 ± 4.9 (CLR1502) × 10(-5) cm/min) compared with BBB-impermeable sucrose (13 ± 2.5) and BBB-permeable diazepam (170 ± 29). Only the fluorescent APC analogues (CLR1501, CLR1502) underwent BCRP and MRP polarized drug efflux transport in the brain-to-blood direction of the BBB model, and this efflux can be specifically blocked with pharmacological inhibition. None of the tested APC analogues appeared to undergo substantial P-gp transport. Limited permeability of the APC analogues across an intact BBB into normal brain likely contributes to the high tumor to background ratios observed in initial human trials. Moreover, addition of fluorescent moieties to APCs resulted in greater BMEC efflux via MRP and BCRP, and may affect fluorescence-guided applications. Overall, the characterization of APC analogue permeability across human BBB is significant for advancing future brain tumor-targeted applications of these agents.

Entities:  

Keywords:  alkylphosphocholine analogues; blood−brain barrier; brain microvascular endothelial cells; induced pluripotent stem cells

Mesh:

Substances:

Year:  2016        PMID: 27421304      PMCID: PMC5014630          DOI: 10.1021/acs.molpharmaceut.6b00441

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  50 in total

Review 1.  The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery.

Authors:  D R Groothuis
Journal:  Neuro Oncol       Date:  2000-01       Impact factor: 12.300

Review 2.  Drug delivery to the central nervous system: a review.

Authors:  Ambikanandan Misra; S Ganesh; Aliasgar Shahiwala; Shrenik P Shah
Journal:  J Pharm Pharm Sci       Date:  2003 May-Aug       Impact factor: 2.327

Review 3.  CNS drug design: balancing physicochemical properties for optimal brain exposure.

Authors:  Zoran Rankovic
Journal:  J Med Chem       Date:  2015-01-06       Impact factor: 7.446

4.  Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy.

Authors:  Jamey P Weichert; Paul A Clark; Irawati K Kandela; Abram M Vaccaro; William Clarke; Marc A Longino; Anatoly N Pinchuk; Mohammed Farhoud; Kyle I Swanson; John M Floberg; Joseph Grudzinski; Benjamin Titz; Anne M Traynor; Hong-En Chen; Lance T Hall; Christopher J Pazoles; Perry J Pickhardt; John S Kuo
Journal:  Sci Transl Med       Date:  2014-06-11       Impact factor: 17.956

Review 5.  Trends in fluorescence image-guided surgery for gliomas.

Authors:  Jonathan T C Liu; Daphne Meza; Nader Sanai
Journal:  Neurosurgery       Date:  2014-07       Impact factor: 4.654

6.  Near-infrared imaging of brain tumors using the Tumor Paint BLZ-100 to achieve near-complete resection of brain tumors.

Authors:  Pramod V Butte; Adam Mamelak; Julia Parrish-Novak; Doniel Drazin; Faris Shweikeh; Pallavi R Gangalum; Alexandra Chesnokova; Julia Y Ljubimova; Keith Black
Journal:  Neurosurg Focus       Date:  2014-02       Impact factor: 4.047

7.  Biological disposition and imaging of a radioiodinated alkylphosphocholine in two rodent models of breast cancer.

Authors:  M A Rampy; R S Brown; A N Pinchuk; J P Weichert; R W Skinner; S J Fisher; R L Wahl; M D Gross; S P Ethier; R E Counsell
Journal:  J Nucl Med       Date:  1996-09       Impact factor: 10.057

8.  Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model.

Authors:  Sumio Ohtsuki; Chiemi Ikeda; Yasuo Uchida; Yumi Sakamoto; Florence Miller; Fabienne Glacial; Xavier Decleves; Jean-Michel Scherrmann; Pierre-Olivier Couraud; Yoshiyuki Kubo; Masanori Tachikawa; Tetsuya Terasaki
Journal:  Mol Pharm       Date:  2012-12-11       Impact factor: 4.939

9.  Synthesis and biological evaluation of radioiodinated phospholipid ether stereoisomers.

Authors:  M A Rampy; A N Pinchuk; J P Weichert; R W Skinner; S J Fisher; R L Wahl; M D Gross; R E Counsell
Journal:  J Med Chem       Date:  1995-08-04       Impact factor: 7.446

10.  P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model.

Authors:  Chris E Adkins; Rajendar K Mittapalli; Vamshi K Manda; Mohamed I Nounou; Afroz S Mohammad; Tori B Terrell; Kaci A Bohn; Celik Yasemin; Tiffany R Grothe; Julie A Lockman; Paul R Lockman
Journal:  Front Pharmacol       Date:  2013-11-04       Impact factor: 5.810

View more
  17 in total

1.  PET/CT imaging of the diapeutic alkylphosphocholine analog 124I-CLR1404 in high and low-grade brain tumors.

Authors:  Lance T Hall; Benjamin Titz; H Ian Robins; Bryan P Bednarz; Scott B Perlman; Jamey P Weichert; John S Kuo
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-09-01

2.  [124I]CLR1404 PET/CT in High-Grade Primary and Metastatic Brain Tumors.

Authors:  Lance T Hall; Benjamin Titz; Nishanta Baidya; Anja G van der Kolk; H Ian Robins; Mario Otto; Scott B Perlman; Jamey P Weichert; John S Kuo
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

3.  In Vitro Models of the Blood-Brain Barrier.

Authors:  Winfried Neuhaus
Journal:  Handb Exp Pharmacol       Date:  2021

Review 4.  New experimental models of the blood-brain barrier for CNS drug discovery.

Authors:  Mohammad A Kaisar; Ravi K Sajja; Shikha Prasad; Vinay V Abhyankar; Taylor Liles; Luca Cucullo
Journal:  Expert Opin Drug Discov       Date:  2016-11-07       Impact factor: 6.098

5.  In Vitro Models of the Human Blood-Brain Barrier Utilising Human Induced Pluripotent Stem Cells: Opportunities and Challenges.

Authors:  Iqra Pervaiz; Abraham J Al-Ahmad
Journal:  Methods Mol Biol       Date:  2022

6.  Diapeutic cancer-targeting alkylphosphocholine analogs may advance management of brain malignancies.

Authors:  Ray R Zhang; Kyle I Swanson; Lance T Hall; Jamey P Weichert; John S Kuo
Journal:  CNS Oncol       Date:  2016-09-12

Review 7.  NIH workshop report on the trans-agency blood-brain interface workshop 2016: exploring key challenges and opportunities associated with the blood, brain and their interface.

Authors:  Margaret J Ochocinska; Berislav V Zlokovic; Peter C Searson; A Tamara Crowder; Richard P Kraig; Julia Y Ljubimova; Todd G Mainprize; William A Banks; Ronald Q Warren; Andrei Kindzelski; William Timmer; Christina H Liu
Journal:  Fluids Barriers CNS       Date:  2017-05-01

Review 8.  Studying Heterotypic Cell⁻Cell Interactions in the Human Brain Using Pluripotent Stem Cell Models for Neurodegeneration.

Authors:  Liqing Song; Yuanwei Yan; Mark Marzano; Yan Li
Journal:  Cells       Date:  2019-04-01       Impact factor: 6.600

9.  Yeast display biopanning identifies human antibodies targeting glioblastoma stem-like cells.

Authors:  Michael Zorniak; Paul A Clark; Benjamin J Umlauf; Yongku Cho; Eric V Shusta; John S Kuo
Journal:  Sci Rep       Date:  2017-11-20       Impact factor: 4.379

10.  Modeling Group B Streptococcus and Blood-Brain Barrier Interaction by Using Induced Pluripotent Stem Cell-Derived Brain Endothelial Cells.

Authors:  Brandon J Kim; Olivia B Bee; Maura A McDonagh; Matthew J Stebbins; Sean P Palecek; Kelly S Doran; Eric V Shusta
Journal:  mSphere       Date:  2017-11-01       Impact factor: 4.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.